Acquired BCR-ABL1 fusion and IDH1 clonal evolution following BCL2 inhibitor treatment in refractory acute myeloid leukemia

Leuk Res. 2021 Jan:100:106494. doi: 10.1016/j.leukres.2020.106494. Epub 2020 Dec 15.

Authors

Diego Adrianzen-Herrera¹, Ximena Jordan-Bruno², Katherine A Devitt³, Joanna L Conant³, Juli-Anne Gardner³

Affiliations

¹ Division of Hematology and Oncology, Larner College of Medicine at the University of Vermont, Burlington, VT, USA. Electronic address: dadrianz@med.uvm.edu.
² Division of Hematology and Oncology, Larner College of Medicine at the University of Vermont, Burlington, VT, USA.
³ Department of Pathology and Laboratory Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, USA.

PMID: 33387682
DOI: 10.1016/j.leukres.2020.106494

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Agents / adverse effects
Bridged Bicyclo Compounds, Heterocyclic / adverse effects*
Clonal Evolution / drug effects*
Drug Resistance, Neoplasm*
Fusion Proteins, bcr-abl / genetics*
Humans
Isocitrate Dehydrogenase / genetics*
Leukemia, Myeloid, Acute / drug therapy
Leukemia, Myeloid, Acute / genetics
Leukemia, Myeloid, Acute / pathology*
Male
Prognosis
Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors*
Sulfonamides / adverse effects*

Substances

Antineoplastic Agents
BCL2 protein, human
Bridged Bicyclo Compounds, Heterocyclic
Proto-Oncogene Proteins c-bcl-2
Sulfonamides
Isocitrate Dehydrogenase
IDH1 protein, human
Fusion Proteins, bcr-abl
venetoclax